Celairis Secures Exclusive Rights to Commercialize Ocugen's OCU400 in ASEAN and Australia
What happened
Celairis received exclusive rights to commercialize OCU400, an investigational gene therapy for retinitis pigmentosa, in Australia, New Zealand, and member states of the Association of Southeast Asian Nations. Under the agreement, Ocugen receives an upfront license fee, potential development and milestone payments totaling up to $7.1 million, and 50% of gross profits from net sales in the region. Celairis will be responsible for regional regulatory submissions and commercialization efforts.
From manilatimes.net
Why it matters
The deal expands access to a potential one-time treatment gene therapy across a region estimated to have 725 million people. The agreement provides Ocugen with significant financial terms, including a high single-digit percentage royalty on net sales.
From manilatimes.net
Who's involved
- OcugenBiopharmaceutical company whose gene therapy OCU400 is being commercialized
- Association of Southeast Asian NationsRegional market where the commercialization rights extend
- Global Alliance for Regenerative MedicineHealthcare organization that might benefit from increased market access to the therapy
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- OcugenSpeculative
Could see increased revenue from the upfront fee, milestone payments, and gross profit royalties from the new regional rights.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Ocugen
biopharmaceutical company
Nothing else this week.
-
Association of Southeast Asian Nations
international organisation of Southeast Asian countries